It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...

Although the media and the public are worried about the infectious risks of transfusion, hemovigilance reports show that antigen-antibody reactions are responsible for the vast majority of acute ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and ...

A novel nanobody-based immunosensor, designed to function stably in undiluted biological fluids and harsh conditions, has ...

For life science startups, the road to innovation often begins with accurate and reliable diagnostic tools. Whether it’s identifying diseases or contributing to groundbreaking research, diagnostic ...

A novel nanobody-based immunosensor, designed to function stably in undiluted biological fluids and harsh conditions.

A novel nanobody-based immunosensor, designed to function stably in undiluted biological fluids and harsh conditions, has been developed, as reported ...

Bispecific antibodies have been big news for several years at the ... This study evaluated the efficacy of elranatamab ...

Here, they are captured by the APCs, which then cause apoptosis among the antigen-specific ... cytotoxic/cytolytic reactions involving the interaction of IgG or IgM antibodies and complement ...

CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...

In recent years, several ADC drugs have achieved sales exceeding 1 billion USD, drawing significant market attention. This rise in ADC drug ...

Immutep Ltd (ASX:IMM) has reported a small-scale conceptual safety test among 49 patients using flagship drug IMP761 has seen ...